Assertion Supported AI assessment confidence: 80% certainty 4/5 debate potential 1/5

Recombine offers a 250-disease genetic test for under $500 out-of-pocket

Alexander Bisignano · Alexander Bisignano, Recombine // Genetic Testing // Data Driven NYC (FirstMark Capital) · Feb 18, 2015 · at 15:06

Alexander Bisignano, CEO of Recombine, explains how Recombine's multiplexed genomic screening compares to traditional single-gene tests from legacy diagnostic labs.

0:00 / 0:07exact quote · 7.4s

▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark

“We developed a test that can do 250 of the most common diseases of this nature for under 500 dollars to patients that don't have private insurance”

quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →

The claim, plainly

Recombine developed a genetic carrier screening test that screens for 250 common genetic diseases for under $500 for patients without private insurance.

a quote alone can be ambiguous, so this restates it with the references and context of the conversation around it resolved. AI-written; the tape below the player is the source.

Assessment

Then-CEO Alexander Bisignano claimed in February 2015 that Recombine developed a genetic carrier screening test evaluating 250 common genetic diseases for under $500 out-of-pocket for patients without private insurance. Both components of the statement are substantiated. Corporate filings and press releases, including Sequenom's 2015 SEC Form 10-K for the HerediT UNIVERSAL partnership and later Cooper Companies documentation, confirm Recombine's CarrierMap panel screened for over 250 genetic conditions. Furthermore, while Recombine did not publish a standardized retail list price in press releases, patient and clinical accounts from 2015 confirm that patients lacking insurance coverage were offered out-of-pocket self-pay rates ranging from $75 to $350, satisfying the under $500 condition.

Sequenom Laboratories' 2015 SEC Form 10-K filing confirmed Recombine's carrier screening test panel covered over 250 genetic disorders.
Patient and clinical forum records from 2015 document that uninsured patients were offered self-pay cash settlements between $75 and $350 out-of-pocket by Recombine.

Checked against

[1] tracxn.com [2] prnewswire.com [3] sec.gov [4] igls.net [5] igls.net [6] coopercos.com [7] sec.gov [8] nsgc.org

"Recombine" "CarrierMap" "$350" OR "$399" OR "$499" OR "$500" OR "500" "HerediT UNIVERSAL" "Recombine" "Recombine" "CarrierMap" "500" OR "dollars" OR "cost" OR "price" "Recombine" "250" "CarrierMap" "Recombine" carrier screening cash price OR cash-pay OR self-pay "Recombine" "uninsured" OR "without insurance" OR "out-of-pocket" "$350" OR "$399" OR "$499" OR "$500" "Recombine" carrier screening price OR cost 2014 OR 2015 Alexander Bisignano Recombine CarrierMap cost 500 Recombine CarrierMap 250 genetic diseases OR conditions

assessed as of 2026-07-31

This assessment is an AI reading of a public statement, made against the cited references with the confidence shown. It can be wrong. The quote, the tape and the references are all on this page; if something is off, use report an error below. full disclaimer →

Mentioned

genetic testing Recombine

⚑ Spot an error? Report it

More from Alexander Bisignano

Assertion Partly supported

Bisignano: Science has not truly sequenced the entire human genome

“We actually haven't truly sequenced the whole human genome just because there's so much variation that we can't capture yet.”

Alexander Bisignano Feb 18, 2015 ▶ 13:49 Alexander Bisignano, Recombine // Genetic Testing // Data Driven NYC (FirstMark Capital)

Opinion

Bisignano: LabCorp and Quest hold an oligopoly on insurance contracts

“LabCorp and Quest have sort of an oligopoly on insurance contracts, and people tend to stay in network.”

Alexander Bisignano Feb 18, 2015 ▶ 21:02 Alexander Bisignano, Recombine // Genetic Testing // Data Driven NYC (FirstMark Capital)

Opinion

Bisignano: Major diagnostic companies Quest and LabCorp lack agile software teams

“Most laboratory diagnostic companies are not set up as software companies. Example, Quest and LabCorp. Two largest companies in the country that do laboratory testing. Twelve billion dollar market cap. They are not agile software teams.”

Alexander Bisignano Feb 18, 2015 ▶ 4:55 Alexander Bisignano, Recombine // Genetic Testing // Data Driven NYC (FirstMark Capital)

Assertion Supported

Bisignano: Most genetic research is based on European and Jewish populations

“Most of genetics actually is based on studying European and Jewish individuals just because that's been the body of literature that's been developed over the past few decades.”

Alexander Bisignano Feb 18, 2015 ▶ 13:02 Alexander Bisignano, Recombine // Genetic Testing // Data Driven NYC (FirstMark Capital)

Assertion Not checkable as stated

Bisignano: Recombine achieves over 65% patient opt-in rate for research

“We see a 65% or more opt-in from most of the centers”

Alexander Bisignano Feb 18, 2015 ▶ 19:08 Alexander Bisignano, Recombine // Genetic Testing // Data Driven NYC (FirstMark Capital)

Assertion Contradicted

Bisignano: Human genome sequencing costs fell from $3B to $1,000

“We finished the human genome, and then for the next decade, the human genome, the cost to sequence it went from three billion down to 1000.”

Alexander Bisignano Feb 18, 2015 ▶ 4:16 Alexander Bisignano, Recombine // Genetic Testing // Data Driven NYC (FirstMark Capital)

Recombine offers a 250-disease genetic test for under $500 out-of-pocket

More from Alexander Bisignano

Turn any episode into a week of clips.